It was a volatile but ultimately positive week on Wall Street, marked by renewed tensions in the U.S.-China trade war and a ...

LONDON/COPENHAGEN (Reuters) -Novo Nordisk has appointed U.S. pharmaceutical executive Greg Miley as its new global head of ...

Following the “remarkable” success of the inaugural ACT Summit held in Dubai in May, Novo Nordisk Qatar, under Ebn Sina Medical Company hosted the second edition of ACT ...

Doctors called it “huge for patients,” if true. Patients who’ve struggled to afford the pricey medicines shared hope the ...

The drug, called Rybelsus, is the only oral GLP-1 medication available. It was previously approved to treat Type 2 diabetes ...

Novo Nordisk is set to buy a blood disease drug from Omeros for up to $2.1 billion. Bristol Myers Squibb acquired Orbital Therapeutics for $1.5 billion. Boehringer Ingelheim offered up to $991 million ...

Danish drugmaker Novo Nordisk (NVO) slipped 6% in early trading on Friday after U.S. President Donald Trump said on Thursday ...

Omeros signs an up to $2.1 billion licensing deal with Novo Nordisk. Here's why the NVO agreeement is constructive for OMER ...

Shares of Omeros Corp skyrocketed 155% to $10.43 this morning, following the news of an asset purchase agreement with Novo ...

Microdosing GLP-1 weight loss drugs like semaglutide may come with benefits like lower cost and fewer side effects, but ...